Shots:

• Terrosa is a parathyroid hormone (PTH) gene recombination candidate originally developed by Richter-Helm Biotec to treat osteoporosis in men and postmenopausal women including those at high risk of fracture. Additionally- Terrosa has completed its P-I and P-III trials in EU and Japan has shown an increase in bone density in the spine- femur- and hip joint
• The 4-year post marketing surveillance study is conducted as the drug is listed in equivalent biologic treatment to the reference product. The launch was successful as the patent for "stable teriparatide solution" and "increasing bone toughness and rigidity and fracture reduction method" expired in Dec 2018 and Aug 2019 respectively
• In 2017- EMA approved Terrosa and was launched in EU and the US but not as biosimilar in Aug 2019 in 2019 respectively

Click here to read full press release/ article | Ref: Center for Biosimilars | Image: Behance